At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously for 8 Weeks to Hypertensive Subjects With Uncontrolled Blood Pressure
In Brief
A Phase 2 clinical trial evaluating Placebo and ISIS 757456 for Hypertension. Completed, enrolled 26 participants across 9 sites.
Detailed Summary
This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartNov 2019
Primary CompletionJul 2020
TodayJul 2026
First PostedSep 10, 2019
Enrollment StartNov 13, 2019
Primary CompletionJul 20, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.8 years ago
Interventions
Placebodrug
ISIS 757456-matching placebo solution administered as SC injection.
ISIS 757456drug
ISIS 757456 administered as SC injection.